Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYEALO)

Drug Name

TMC-647055 Drug Info

Synonyms

TMC647055; 1204416-97-6; TMC-647055; UNII-11BD024G7J; TMC 647055; 11BD024G7J; 113-cyclohexyl-13-methoxy-5,11-dimethyl-17H-8-oxa-4-thia-3,5,11-triaza-1(10,6)-benzo[3,4]azepino[1,2-a]indolacyclododecaphane-2,12-dione 4,4-dioxide; TMC647055 Choline; SCHEMBL1239667; CHEMBL2043025; DTXSID90152860; BDBM243456; EX-A1252; AOB87185; BCP06459; ZINC84726167; AKOS030627003; SB16907; DB11822; NCGC00482982-02; DA-47229; BC600546; 2,19-Methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9H,15H)-dione, 27-cycl

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 1	[1]

Cross-matching ID

PubChem CID: 44556044
CAS Number: CAS 1204416-97-6
TTD Drug ID: DMYEALO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PSI-7977	DMLSUWZ	HCV 1-6 infection	1E51	Approved	[3]
Setrobuvir	DMTNDM2	Hepatitis C virus infection	1E51.1	Phase 2	[4]
BI 207127	DMMSGAT	Hepatitis C virus infection	1E51.1	Phase 2	[5]
Valopicitabine dihydrochloride	DMFWZ2U	Virus infection	1A24-1D9Z	Phase 2	[6]
INX-189	DMSTJ6Q	Hepatitis C virus infection	1E51.1	Phase 2	[7]
Tegobuvir	DM6YI5T	Hepatitis C virus infection	1E51.1	Phase 2	[8]
VX-759	DMJUSM8	Hepatitis C virus infection	1E51.1	Phase 2	[9]
VX-135	DMZ3FE8	Hepatitis C virus infection	1E51.1	Phase 2	[10]
VX-222	DMO3U4W	Hepatitis C virus infection	1E51.1	Phase 2	[9]
BMS 791325	DMKH4PI	Hepatitis C virus infection	1E51.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)	TTMVBWH	POLG_HCV1	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01202825) TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single OralDoses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients. U.S. National Institutes of Health.
2	WO patent application no. 2014,1522,75, Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055.
3	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
5	2011 Pipeline of Boehringer Ingelheim Pharma.
6	Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
7	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
8	Clinical pipeline report, company report or official report of Gilead (2011).
9	2011 Pipeline of Vertex.
10	All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11.
11	2011 Pipeline of Bristol-Myers Squibb.